(Q38270497)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Current and future treatment of amyloid neuropathies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Vincent Algalarrondo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Cecile Cauquil

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Marie Theaudin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Antoine Rousseau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Michel S Slama

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

21 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1437-1451

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

Hereditary and acquired amyloid neuropathies

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

The molecular biology and clinical features of amyloid neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Online registry for mutations in hereditary amyloidosis including nomenclature recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

FAP neuropathy and emerging treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Transthyretin deposition in familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Progression of transthyretin amyloid neuropathy after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Regional difference and similarity of familial amyloidosis with polyneuropathy in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Genotypic and phenotypic correlation in an Italian population of hereditary amyloidosis TTR-related (HA-TTR): clinical and neurophysiological aids to diagnosis and some reflections on misdiagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Genotype, echocardiography, and survival in familial transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Primary amyloidosis presenting as upper limb multiple mononeuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Awareness and motives for use and non-use of preimplantation genetic diagnosis in familial amyloid polyneuropathy mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Antibody therapy for familial amyloidotic polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Systemic light chain amyloidosis: an update for treating physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Liver Transplantation for Familial Amyloidotic Polyneuropathy (FAP): A Single-Center Experience Over 16 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Symptomatic and provende novoamyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Effect of liver transplantation on the survival of patients with ordinary onset familial amyloid polyneuropathy in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.983905

10.1586/14737175.2014.983905

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416603%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference